118
Participants
Start Date
April 25, 2011
Primary Completion Date
March 12, 2021
Study Completion Date
March 12, 2021
CC-115
"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
Memorial Sloan-Kettering Cancer Center, New York
Hospital de Donosti, San Sebastián (Guipuzcoa)
Hospital Universitario Madrid Sanchinarro, Madrid
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute Drug Development Unit, Nashville
Hospital Virgen del Rocio, Seville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Henry Ford Medical Center - New Center One, Detroit
Uniklinik Koln, Cologne
Mary Crowley Medical Research Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Cedars-Sinai Medical Center, Los Angeles
UCLA, Los Angeles
University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco
Gustave Roussy, Villejuif
Universitatsklinikum Wurzburg, Würzburg
Hospital Val d'Hebron, Barcelona
Lead Sponsor
Celgene
INDUSTRY